Compare TYRA & ARCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | ARCO |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | Uruguay |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2021 | 2011 |
| Metric | TYRA | ARCO |
|---|---|---|
| Price | $20.07 | $7.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 9 |
| Target Price | ★ $47.45 | $11.23 |
| AVG Volume (30 Days) | 957.1K | ★ 1.9M |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | ★ 3.45% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $12.75 |
| Revenue Next Year | N/A | $6.01 |
| P/E Ratio | ★ N/A | $7.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.35 | $6.67 |
| 52 Week High | $40.65 | $9.75 |
| Indicator | TYRA | ARCO |
|---|---|---|
| Relative Strength Index (RSI) | 35.51 | 52.77 |
| Support Level | $18.66 | $7.60 |
| Resistance Level | $27.00 | $8.40 |
| Average True Range (ATR) | 1.12 | 0.27 |
| MACD | -0.14 | 0.10 |
| Stochastic Oscillator | 7.94 | 73.27 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Arcos Dorados Holdings Inc operates McDonald's branded restaurants in various countries and territories in Latin America and the Caribbean. The Company manages its business as distinct geographic segments and its operations are divided into three geographic divisions, as follows: Brazil, the North Latin American division, or NOLAD, which is comprised of Costa Rica, Mexico, Panama, Puerto Rico, Martinique, Guadeloupe, French Guiana and the U.S. Virgin Islands of St. Croix and St. Thomas and the South Latin American division, or SLAD, which is comprised of Argentina, Chile, Ecuador, Peru, Uruguay, Colombia, Venezuela, Trinidad and Tobago, Aruba and Curacao. Its menu includes hamburgers, McNuggets, salad, sandwiches, French fries, and others. It generates maximum revenue from Brazil.